Views & Analysis | Perspectives on pharma industry issues

R&D

Women in STEM: Balancing the field from the beginning

pharmaphorum spoke with three female experts from Thermo Fisher Scientific about women in STEM today and tomorrow.

R&D

Map with medicines and pipette superimposed for global clinical trials concept

The devil’s in the details: Navigating complexity & nuance i...

Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.

R&D

Innovative direct delivery strategies to unlock oligonucleot...

Oligo therapies are emerging as promising therapeutics with the potential to address previously untreatable conditions.

Market Access

weight loss injections and measuring tape

Fighting fake GLP-1s to protect patients & preserve trust

Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.

Digital

artificial intelligence chip with connected lines

Sponsored

Remove the friction to unlock the true potential of AI: Prec...

Frictionless AI is the foundation for Precision Intelligence: insight that is not simply faster or broader, but more decision-relevant.

Digital

Trust and treatment: GenAI in life sciences in 2024

In 2023, the life sciences industry was rocked by generative artificial intelligence. This year, we'll see some of these ideas become reality.

Sales & Marketing

The Omni Advantage: A concise roadmap for change, for the pe...

The book launch for pharma industry veteran and award-winning businesswoman Merhnaz Campbell’s The Omni Advantage: Accelerating the Behavioural Change with Omnichannel in Pharma Sales E

Market Access

A year of major M&A ahead?

The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.

Sales & Marketing

Sponsored

Solution Spotlight: Own The Moments That Matter Most

Medscape Contextual Moments is a suite of integrated opportunities that deliver messaging alongside independent Medscape trusted editorial content.

Sales & Marketing

Sponsored

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Digital

Sponsored

Remove the friction to unlock the true potential of AI: Prec...

Frictionless AI is the foundation for Precision Intelligence: insight that is not simply faster or broader, but more decision-relevant.

Digital

Controlling AI hallucinations: Building evidence-based trust...

When it comes to GenAI, industry must demand evidence-grounded systems that prioritise verifiable clinical data and rigorous human oversight.

Market Access

Fighting fake GLP-1s to protect patients & preserve trust

Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.

Market Access

Capital discipline in biotech: Building enduring companies w...

Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

pharmaphorum podcast Episode 256, Dean Erhardt, D2 Solutions

Providing patient access to new therapies, with Dean Erhardt

Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.

Patients

Pharmacist with patient and prescription

From access to advocacy: Turning patients into brand champio...

Done right, DTP is not just filling scripts. It is building loyalty that turns satisfied patients into lifelong advocates.

Patients

Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

Women in STEM: Balancing the field from the beginning

The devil’s in the details: Navigating complexity & nuance i...

Innovative direct delivery strategies to unlock oligonucleot...

Fighting fake GLP-1s to protect patients & preserve trust

Remove the friction to unlock the true potential of AI: Prec...

Trust and treatment: GenAI in life sciences in 2024

The Omni Advantage: A concise roadmap for change, for the pe...

A year of major M&A ahead?

Solution Spotlight: Own The Moments That Matter Most

Pushing through barriers to commercial launch success, with ...

Remove the friction to unlock the true potential of AI: Prec...

Controlling AI hallucinations: Building evidence-based trust...

Fighting fake GLP-1s to protect patients & preserve trust

Capital discipline in biotech: Building enduring companies w...

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Providing patient access to new therapies, with Dean Erhardt

From access to advocacy: Turning patients into brand champio...

Rewriting the MASLD playbook

Women in STEM: Balancing the field from the beginning

The devil’s in the details: Navigating complexity & nuance i...

Innovative direct delivery strategies to unlock oligonucleot...

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks